List of Vendor Companies in Finland - 18

Afekta is a metabolomics service provider specialized in microbiota-associated compounds and bioactive phytochemicals present in plant-based foods. They can analyze any biological sample and measure a wide variety of metabolites, with no need to choose a list of compounds in advance!

Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis, across a variety of fields from oncology to neuroscience and more. From empowering researchers in the identification of novel biomarkers of disease, and supporting R&D scientists in speeding up time-to-market of novel drugs, to helping pathologists enhance the accuracy of cancer diagnostics — Aiforia has the expertise and experience to transform healthcare all the way from discovery to diagnosis.

Bioretec Ltd. is a medical device company focusing on the development of strong, safe and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. Our products are used worldwide, and we continue to further develop materials and products for load-bearing clinical applications.

Bone Index Ltd. is a medical device company with the game-changer point-of-care technology (Bindex®) in osteoporosis screening/diagnostics. The overall aim is to prevent osteoporotic fractures, improve surgical outcomes, and improve the quality of life for families in the United States.

CurifyLabs is a Finnish healthtech company developing solutions for manufacturing personalized medicines in pharmacies and hospitals. CurifyLabs is revolutionizing the way personalized medicines are created. We provide innovative technology that enables the automation of compounding—transforming a traditionally manual, time-intensive process into a streamlined, efficient, and accurate system. The CurifyLabs' Compounding System Solution (CSS) is an automated pharmaceutical compounding platform for non-sterile dosage forms, including tablets, troches, liquids, suppositories, vagitories, ointments and capsules. It enables better treatments for patients and improved efficiency for pharmacies and hospital pharmacies. In addition to cost savings, it ensures high manufacturing standards at the point of care through in-process quality control. The CSS is a user-friendly platform consisting of: GMP manufactured excipient bases, compounding robotics, integrated quality control tools, software and a comprehensive formulation library to meet versatile compounding needs of pharmacies.. CurifyLabs’ CSS technology is currently in use for patients by customers in Europe and US. The CurifyLabs Compounding System Solution offers an easy-to-use, turnkey solution for pharmacists and hospitals, making personalized medication production faster, safer, and more accessible to patients in need. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius.

DelSiTech is a drug delivery and drug development company based in Turku, Finland. DelSiTech has developed a unique proprietary technology making it a world leader in advanced biodegradable silica-based drug delivery. The technology has successfully been applied to the controlled release of small molecules, biopharmaceuticals and viral vectors with a focus on parenteral and local administration. We can work with you from early feasibility testing to clinical proof of concept; the technology can also be licensed to industry partners. With the DelSiTechTMSilica Matrix, we can create novel products, provide alternative administration opportunities, and extend and manage the life cycle of existing products. More patient-friendly products can be developed which release active compounds over days to many months. The technology is also well suited for challenging drug delivery needs such as controlled local delivery to the eye or the brain. At DelSiTech, we are also developing our own in-house supergeneric drug products for significant unmet medical and market needs. Our lead product, 1308, is a 3 month subcutaneous product for hepatitis B. 1308 will enter clinical studies in Q1 2017.

Euformatics provides expert computational services at the intersection of life sciences and software. Our mission is to bridge the gap between practicing life scientists and creators of new data analysis and modeling methods, accelerating the transition to precision medicine. Our focus is in adapting cutting-edge research in computational methods and putting them to practice. Our customers are biotech companies and healthcare providers in Finland and abroad.

Genevia Technologies is a Finnish CRO specialized in delivering diverse bioinformatics solutions. The company was founded in 2011 as a spin-off enterprise by a group of computational systems biology researchers from Tampere University of Technology, in Tampere, Finland. Over a course of 15 years, our team has built up an extensive experience in analyzing and integrating various microarray, next-generation sequencing and proteomics data. We have also been developing and applying systems biological and mathematical modeling techniques on a wide range of applications from bacterial metabolomics to genomics of human cancers. Our mission is to facilitate the use of high-throughput genetic measurements and biological big data in life science companies and research institutions. We provide general genomics and bioinformatics consultation, support in experimental design, acquisition of cost-effective experiments, analysis and integration of data, and design of custom data analysis and visualization pipelines that organizations can use to analyze their data independently. You can find more information about our company, services and customers on our website at http://www.geneviatechnologies.com

HVR Cardio is a medical device company focused on developing first-generation transcatheter mitral valve repair solutions. Our minimally invasive technology has the potential to enable safer, faster, and less traumatic cardiac interventions for mitral regurgitation patients worldwide. HVR Cardio's innovative HELIX ring technology has been carefully designed to fit the anatomy of the mitral valve. This allows fast and easy implantation and most importantly, restoration of the valve geometry leading to uncompromised clinical efficacy. With our catheter-based product, we expect to reduce the invasiveness, operation time, and morbidity associated with mitral valve repair operations. This would allow effective treatment of patients at any stage of mitral valve disease, including those who currently have no treatment options. HVR Cardio's patented HELIX ring technology, which is currently at an advanced development stage, can be applied to interventional cardiology as well as to cardiac surgery. Visit hvrcardio.com to learn more.

Scientific Excellence for IVD. With over 30 years of experience Hytest offers antibodies and antigens for improved patient outcomes in such areas as cardiac markers, infectious, neuroscience and autoimmune disease reagents.

LymphaTouch is a pioneering Finnish healthcare technology company manufacturing medical devices for manual therapy and rehabilitation professionals. The patented LymphaTouch technology effectively reduces swelling and mobilizes soft tissue by applying controlled negative pressure and mechanical vibration. LymphaTouch Oy is a ISO13485 certified medical device manufacturer and our products are CE and US FDA registered medical devices.

Mobidiag is a biotechnology company specializing in developing and marketing novel, innovative solutions for molecular diagnostics of infectious diseases.COVID-19: Received Emergency Use Authorization in Finland for its Amplidiag COVID-19 real-time PCR

NADMED Oy is a startup company bringing to market a new accurate high-throughput method to measure NADs from whole blood and other sample matrices.

Nexstim is a Finnish, globally operating medical technology company. Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on Nasdaq First North Growth Market Finland.

Onego Bio is a US-Finnish food-biotech company revolutionizing the food system by harnessing the power of precision fermentation to manufacture real egg protein entirely animal-free. Their ingredient, Bioalbumen®, sets a new standard for sustainable protein with identical taste and nutrition, superior functional properties and over 90% smaller environmental footprint compared to eggs from chickens. Onego's highly efficient and scalable technology caters to the needs of the food industry searching for stable, sustainable functional ingredients. As a game-changer in the field, the company was selected the Winner of Fast Company's 2023 World Changing Ideas awards and is a co-founder of two industry associations: Precision Fermentation Alliance and Food Fermentation Europe.

In many fields of surgery and dentistry, bone has to be cut or removed without damaging the proximal soft structures. Surgify develops new solutions to protect these structures and prevent associated complications. Bleeding, infections and nerve injuries are some of the complications that can severely affect a patients quality of life. Surgify technology improves the safety, speed and precision of bone surgery to minimize these risks.

Three Finnish life science experts have joined forces to form Uniogen, a global pioneer in diagnostic solutions and point-of-care testing. Building on the strong track record of Abacus Diagnostica, Kaivogen and Labrox,

Zora Biosciences Oy is a diagnostics company that identifies markers of disease and develops them into robust high-throughput, value-added clinical methods, with a main focus on cardiovascular disease, offering the CERT - Coronary Event Risk Test.